iAnthus Capital Holdings, Inc.
iAnthus Capital Holdings, Inc.
Your view on IAN.CN
Overview
What the company does, where it operates, and who runs it.
About iAnthus Capital Holdings, Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Richard Proud
- Headquarters
- US
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Richard Proud
- Headquarters
- US
iAnthus Capital Holdings, Inc. owns and operates licensed cannabis cultivation, processing, and dispensary facilities in the United States.
It offers biomass products, such as pre-rolls; cannabis infused products, including topical creams and edibles; vape cartridges, concentrates, live resins, wax products, oils, and tinctures; cannabidiol products, such as topical creams, tinctures, and sprays, as well as products for beauty and skincare that include lotions, creams, haircare products, lip balms, and bath bombs.
The company engages in the wholesale-distribution and retail of CBD products. It owns and/or operates 32 dispensaries and 10 cultivation and/or processing facilities in 8 states. The company was founded in 2014 and is headquartered in New York, New York.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for iAnthus Capital Holdings, Inc., and the rating behind it. IAN.CN last traded at C$0.0050; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for iAnthus Capital Holdings, Inc.. Starting points for iAnthus Capital Holdings, Inc.: EPS -C$0.0080, beta -0.47 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for iAnthus Capital Holdings, Inc.. iAnthus Capital Holdings, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for iAnthus Capital Holdings, Inc.. Trailing twelve-month EPS for iAnthus Capital Holdings, Inc. stands at -C$0.0080. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for iAnthus Capital Holdings, Inc.. iAnthus Capital Holdings, Inc. has reported as a listed company since 2016. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
iAnthus Capital Holdings, Inc. valued side by side against its closest peers. iAnthus Capital Holdings, Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold iAnthus Capital Holdings, Inc., and how their positions are changing. At a C$34.1M market value, institutional positions materially move iAnthus Capital Holdings, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by iAnthus Capital Holdings, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming iAnthus Capital Holdings, Inc.. iAnthus Capital Holdings, Inc. is a C$34.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming iAnthus Capital Holdings, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for iAnthus Capital Holdings, Inc.. Coverage tracks iAnthus Capital Holdings, Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.